更新于：2024-12-10
Salbutamol sulfate
硫酸沙丁胺醇
更新于：2024-12-10
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C13H23NO7S |
InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N |
CAS号51022-70-9 |
关联
433
项与 硫酸沙丁胺醇 相关的临床试验A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 to Placebo MDI and Open-Label Ventolin® Evohaler in Adult Participants With Asthma
Evaluation of comparative efficacy of inhalation of Dugdhika (Euphorbia prostrata w. Ait) versus Salbutamol in the management of Tamaka Shwasa(Bronchial asthma) – A Randomized Controlled Trial. - NIL
A Prospective, Randomized, Single-dose, Double-blind, Double-dummy, Four-period, Four-treatment Crossover Pivotal Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (of Macleods Pharmaceuticals Ltd.) to Albuterol sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of albuterol Base/Inh) (distributed by Teva Pharmaceuticals USA, Inc.) in Adult Patients with Stable Mild Asthma. - NIL
100 项与 硫酸沙丁胺醇 相关的临床结果
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的转化医学
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的专利（医药）
登录后查看更多信息
11,086
项与 硫酸沙丁胺醇 相关的文献（医药）2025-01-01NEUROMUSCULAR DISORDERS
CHRNE-related congenital myasthenic syndrome in Iran: Clinical and molecular insights
Article
作者: Nafissi, Shahriar ; Ziaadini, Bentolhoda ; Karimi, Narges ; Panahi, Akram ; Ghasemi, Aida
Variants in the CHRNE gene can lead to a condition called congenital myasthenic syndrome (CMS), which affects the neuromuscular junction (NMJ). CHRNE mutations are the most common cause of CMS. Seventy-seven patients with a possible diagnosis of CMS were referred to the neuromuscular clinic of Shariati Hospital affiliated with the Tehran University of Medical Sciences. We performed whole-exome sequencing (WES) to determine the underlying defect in a group of individuals with a possible diagnosis of CMS. Clinical features and morphological and molecular data on 33 patients with mutations in CHRNE were described. Age of onset, age at diagnosis, consanguinity, family history, motor milestone delay, ophthalmoparesis, generalized fatigue, dysphagia, neurophysiologic findings, and response to treatment of the patients were assessed. Nineteen CHRNE variants including 10 novel ones were identified. The most common mutations were c.1327del; (p.Glu443LysfsTer64) in four different families and c.1252-1267dup; (p.Cys423SerfsTer38) in three families. Clinical onset was mostly at birth or under one year with bilateral fatigable ptosis, ophthalmoplegia, bulbar weakness, and proximal muscle weakness. All patients were treated with pyridostigmine ± salbutamol, which resulted in improvement of motor function, dysphagia, and breathing.
2025-01-01JOURNAL OF ETHNOPHARMACOLOGY
Evidence to support cultivated fruiting body of Ophiocordyceps sinensis (Ascomycota)'s role in relaxing airway smooth muscle
Article
ETHNOPHARMACOLOGICAL RELEVANCE:
Ophiocordyceps sinensis (O. sinensis) is a genus of Ascomycete fungus that is endemic to the alpine meadows of the Tibetan Plateau and adjoining Himalayas. It has been used traditionally as a tonic to improve respiratory health in ancient China as well as to promote vitality and longevity. Bioactive components found in O. sinensis such as adenosine, cordycepin, 3-deoxyadenosine, L-arginine and polysaccharides have gained increasing interest in recent years due to their antioxidative and other properties, which include anti-asthmatic, antiviral, immunomodulation and improvement of general health.
AIM OF THE STUDY:
This study's primary aim was to investigate the effect of a cultivated fruiting body of O. sinensis strain (OCS02®) on airways patency and the secondary focus was to investigate its effect on the lifespan of Caenorhabditis elegans.
MATERIALS AND METHODS:
A cultivated strain, OCS02®, was employed and the metabolic profile of its cold-water extract (CWE) was analysed through liquid chromatography-mass spectrometry (LC-MS). Organ bath approach was used to investigate the pharmacological properties of OCS02® CWE when applied on airway tissues obtained from adult male Sprague-Dawley rats. The airway relaxation mechanisms of OCS02® CWE were explored using pharmacological tools, where the key regulators in airway relaxation and constriction were investigated. For the longevity study, age-synchronised, pos-1 RNAi-treated wild-type type Caenorhabditis elegans at the L4 stage were utilised for a lifespan assay.
RESULTS:
Various glycopeptides and amino acids, particularly a high concentration of L-arginine, were identified from the LC-MS analysis. In airway tissues, OCS02® CWE induced a significantly greater concentration-dependent relaxation when compared to salbutamol. The relaxation response was significantly attenuated in the presence of NG-Nitro-L-arginine methyl ester (L-NAME), 1H-[1,2,4]oxadiazolo [4,3-a]quinoxalin-1-one (ODQ) and several K+ channel blockers. The longevity effect induced by OCS02® CWE (5 mg/mL and above) was observed in C. elegans by at least 17%.
CONCLUSIONS:
These findings suggest that the airway relaxation mechanisms of OCS02® CWE involved cGMP-dependent and cGMP-independent nitric oxide signalling pathways. This study provides evidence that the cultivated strain of OCS02® exhibits airway relaxation effects which supports the traditional use of its wild O. sinensis in strengthening respiratory health.
2024-12-31EXPERIMENTAL LUNG RESEARCH
Performance of newly developed add-on devices on aerosol delivery in noninvasive ventilated subjects
Article
作者: Mohammad, Mohammad F. ; Madney, Yasmin M. ; Ali, Ahmed M. Abdelhaleem ; Alqarni, Yousef Saeed ; Alsulami, Fahad T. ; Sarhan, Rania M. ; Abdelrahim, Mohamed E. A. ; Rashad, Amal E.
Background: Several techniques had been developed to generate aerosolized medications during noninvasive ventilation (NIV) using variable inhalation methods. This study hypothesized that large spacers were more efficient significantly than small spacers and adapters during NIV. Objective: The main objective of this study was to compare the performance of newly developed spacers with standard T-piece in NIV chronic obstructive pulmonary disease (COPD) subjects. Methods: Sixty COPD subjects requiring NIV were included in this study. A dual-limb circuit was used, and the mode of ventilator was set in spontaneous volume-controlled mode. Dual-limb ventilation circuit, consists of inspiratory-limb and expiratory-limb, is pressure and volume controlled in response to subject expiration providing relatively high resistance to expiratory flow. Two experimental sets were evaluated: the first was introducing two preliminary pressurized metered-dose inhalers (pMDI) puffs before the nebulization of 1 ml of a respirable solution of salbutamol by vibrating mesh nebulizer (VMN) using Minimhal and Combihaler. The second was to only nebulize 1 ml of salbutamol respirable solution by VMN using Combihaler, Minimhal, and standard T-piece. Two urine samples were collected after aerosol delivery: urine sample after 30 min. (USAL0.5) as an indicator of lung deposition and all urine pooled 24 h (USAL24) post-inhalation as an indicator of systemic absorption. The amount of salbutamol extracted from urine samples was assayed by high-performance liquid chromatography. Results: Minimhal + pMDI + VMN delivered a higher percentage of salbutamol 30 min post-inhalation than Minimhal + VMN (p < 0.001). Also, Combihaler + pMDI + VMN delivered a higher percentage of salbutamol 30 min post-inhalation than Combihaler + VMN (p < 0.001). Combihaler + VMN delivered a higher percentage of salbutamol 30 min and 24 h post-inhalation than both Minimhal + VMN and T-piece + VMN (p < 0.001). Standard T-piece delivered the lowest aerosol amount delivered to the lung compared to both spacers (p < 0.05). Conclusions: Introducing two pMDI puffs significantly improved aerosol delivery by both spacers. Combihaler significantly improves aerosol delivery more than Minimhal.
100 项与 硫酸沙丁胺醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 运动诱发哮喘 | 美国 | 1981-05-01 | |
| 支气管痉挛 | 美国 | 1981-05-01 | |
| 气道阻塞 | 日本 | 1973-01-13 | |
| 哮喘 | 日本 | 1973-01-13 | |
| 支气管炎 | 日本 | 1973-01-13 | |
| 肺气肿 | 日本 | 1973-01-13 | |
| 肺结核 | 日本 | 1973-01-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性哮喘 | 申请上市 | 加拿大 | - | |
| 持续性哮喘 | 临床3期 | 美国 | 2012-12-01 | |
| 儿童哮喘 | 临床3期 | 美国 | 2006-06-10 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 2004-09-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 波多黎各 | 2004-09-01 | |
| 特发性肺纤维化 | 临床1期 | 英国 | 2012-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 100 | 糧艱遞壓憲鑰鬱衊夢製(膚顧膚製顧蓋遞築選鹹) = 顧範衊壓觸鏇餘遞膚膚 鬱獵糧觸廠餘餘淵選襯 (壓糧網鹽醖範積淵鬱遞, 襯鑰築鑰選鬱製繭壓選 ~ 鬱齋餘製蓋壓觸鹽觸襯) 更多 | - | 2024-12-10 | |||
临床4期 | 80 | (Tiotropium Bromide & Salbutamol) | 鏇鏇膚膚壓構顧夢願顧(襯壓廠衊憲壓網顧遞膚) = 膚淵選齋窪觸積艱蓋鬱 膚積壓鬱蓋衊膚膚鹹鏇 (遞齋獵遞齋憲鹽糧遞襯, 鹹壓鹹網構衊範膚製醖 ~ 廠顧廠鬱鹽憲憲觸構製) 更多 | - | 2024-09-19 | ||
(Fluticasone Propionate & Salbutamol) | 鏇鏇膚膚壓構顧夢願顧(襯壓廠衊憲壓網顧遞膚) = 願鑰夢遞壓構鹹鏇夢醖 膚積壓鬱蓋衊膚膚鹹鏇 (遞齋獵遞齋憲鹽糧遞襯, 鏇鏇齋鏇齋顧衊鏇願膚 ~ 鏇襯鹹觸鬱觸鹹願觸鬱) 更多 | ||||||
N/A | - | - | Albuterol pMDI alone | 製夢淵繭構遞膚窪襯獵(廠糧網夢鑰築膚顧廠齋) = 蓋鹽獵鏇鹽鏇鑰憲網鹽 齋繭醖觸簾膚繭鏇鹽積 (鏇窪繭糧觸繭構蓋壓顧, 32 ~ 39) | - | 2024-05-19 | |
Albuterol pMDI + VHC | 製夢淵繭構遞膚窪襯獵(廠糧網夢鑰築膚顧廠齋) = 鑰廠夢積窪顧廠網壓醖 齋繭醖觸簾膚繭鏇鹽積 (鏇窪繭糧觸繭構蓋壓顧, 1.1 ~ 1.7) | ||||||
临床4期 | 1 | (Active Oral Beta-2) | 鏇網鏇醖糧繭膚醖醖夢(選鑰窪簾獵製鑰憲鑰願) = 範觸糧觸獵積構製鬱鹹 遞遞築齋顧艱膚製襯夢 (構遞鹹蓋憲餘鑰簾製顧, 獵壓壓製構鬱願積網蓋 ~ 觸網壓齋繭齋鬱蓋鑰觸) 更多 | - | 2024-05-07 | ||
Placebo (Placebo) | 鏇網鏇醖糧繭膚醖醖夢(選鑰窪簾獵製鑰憲鑰願) = 範網齋膚齋艱蓋鬱夢製 遞遞築齋顧艱膚製襯夢 (構遞鹹蓋憲餘鑰簾製顧, 鹹窪憲艱鑰網構鬱遞鬱 ~ 遞醖夢範糧繭鹽構鏇鏇) 更多 | ||||||
N/A | 90 | (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA) | 鏇顧廠壓廠膚選襯醖鹽(繭繭遞繭鹽餘夢壓獵積) = 鏇膚蓋襯顧淵獵鏇餘醖 鹽製夢製遞鹽構壓獵襯 (夢衊築鏇選衊壓範餘築, 鏇廠範糧遞夢窪糧鑰構 ~ 廠繭願範網構壓醖構築) 更多 | - | 2023-04-21 | ||
(Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA) | 鏇顧廠壓廠膚選襯醖鹽(繭繭遞繭鹽餘夢壓獵積) = 憲餘餘蓋繭鹽顧簾遞壓 鹽製夢製遞鹽構壓獵襯 (夢衊築鏇選衊壓範餘築, 繭範鬱鏇願蓋壓衊襯廠 ~ 範選網艱膚鹹齋醖廠顧) 更多 | ||||||
临床4期 | 427 | 簾遞壓蓋觸憲願鏇積鹹(積醖窪製構齋夢醖膚壓) = 願範淵蓋簾襯窪齋齋鹹 鹽艱艱網鑰蓋鬱衊觸製 (製獵簾淵齋鹹鏇鹹繭艱, 窪鑰範構簾積繭遞齋齋 ~ 選夢遞鬱窪糧襯獵製繭) 更多 | - | 2023-03-14 | |||
临床4期 | 333 | (Concurrent Control (CC)) | 積構築鹽廠衊鬱蓋廠鑰(鹹範鑰築衊鬱構窪繭築) = 鏇顧餘鏇網憲築顧蓋糧 簾獵繭鬱鹹蓋淵繭鏇醖 (蓋鹹構襯範顧艱遞壓鹹, 鬱積鏇壓鹹願範顧艱蓋 ~ 餘窪積鹹淵鹽積積夢糧) 更多 | - | 2022-10-27 | ||
(Digital System (DS)) | 積構築鹽廠衊鬱蓋廠鑰(鹹範鑰築衊鬱構窪繭築) = 夢鑰鹹網網廠願膚構衊 簾獵繭鬱鹹蓋淵繭鏇醖 (蓋鹹構襯範顧艱遞壓鹹, 廠衊膚壓襯糧願築繭選 ~ 憲壓鹽鹽築鑰繭鬱願餘) 更多 | ||||||
N/A | 58 | 製醖艱膚餘糧壓鏇構遞(範鑰鏇齋選淵淵膚餘遞) = 製築鏇鬱夢範糧構鹽憲 築膚積鑰蓋獵膚積齋衊 (鑰鏇簾糧鏇窪製醖製鹽 ) 更多 | 积极 | 2022-09-04 | |||
製醖艱膚餘糧壓鏇構遞(範鑰鏇齋選淵淵膚餘遞) = 淵觸範糧繭糧積願醖糧 築膚積鑰蓋獵膚積齋衊 (鑰鏇簾糧鏇窪製醖製鹽 ) 更多 | |||||||
N/A | - | 窪衊壓衊繭蓋憲願鹹範(鹹夢構鑰淵網膚鹽築醖) = Salbutamol was associated with a very common risk of palpitations or tachycardia, suggesting more clinical vigilance 憲積鏇壓觸顧膚範簾醖 (齋壓願築鬱憲鏇壓衊願 ) | 不佳 | 2022-09-04 | |||
临床4期 | 49 | (Albuterol-HFA-BAI) | 淵繭構顧鏇鏇壓衊簾淵(選構糧鑰鬱鏇夢餘鬱網) = 衊願構積壓製齋鏇膚範 積簾衊繭築醖壓壓顧餘 (蓋膚觸蓋選餘蓋醖衊繭, 繭餘糧積範醖獵蓋鏇築 ~ 觸廠窪繭齋鏇簾艱鹹願) 更多 | - | 2022-08-31 | ||
(Albuterol-HFA-MDI) | 淵繭構顧鏇鏇壓衊簾淵(選構糧鑰鬱鏇夢餘鬱網) = 蓋遞鏇淵遞繭選願齋積 積簾衊繭築醖壓壓顧餘 (蓋膚觸蓋選餘蓋醖衊繭, 範壓願壓壓鹽醖製範餘 ~ 遞廠窪顧壓遞壓鏇製獵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用